Breaking News Instant updates and real-time market news.

STMP

Stamps.com

$203.59

-19.79 (-8.86%)

09:26
10/18/18
10/18
09:26
10/18/18
09:26

Stamps.com selloff yesterday on Postal news unwarranted, says B. Riley FBR

Shares of Stamps.com dropped yesterday after the New York Times reported that President Trump plans to withdraw the U.S. from the Universal Postal Union, B. Riley FBR analyst Zach Cummins tells investors in a research note. The news created an "unwarranted" selloff in the shares given the company's limited exposure to China, the analyst contends. Further, Cummins believes potential outcomes from the U.S.'s possible withdrawal could serve as net benefit for Stamps.com over the longer term. The analyst keeps a Buy rating on the stock with a $300 price target.

STMP Stamps.com
$203.59

-19.79 (-8.86%)

06/01/18
06/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Hold at Needham. 2. Xenia Hotels (XHR) initiated with an Outperform at Baird. 3. Stamps.com (STMP) and Pitney Bowes (PBI) were initiated with a Buy at Maxim. 4. Getty Realty (GTY) initiated with a Buy at Ladenburg. 5. Dana (DAN) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/21/18
RILY
06/21/18
NO CHANGE
RILY
Any selloff in Stamps.com represents attractive buying opportunity, says B. Riley FBR
With Stamps.com trading down 12% intraday, B. Riley FBR analyst Kevin Liu reiterated his Buy rating and $300 price target, saying that any sell-off in Stamps.com represents an "attractive buying opportunity" given "the company's entrenched relationship with the USPS and strategic positioning in e-commerce." He added that Trump's proposal to privatize the Post Office, while it would present risks to the company, is still simply speculation at this point.
07/26/18
ROTH
07/26/18
NO CHANGE
Target $305
ROTH
Buy
Stamps.com price target raised to $305 from $255 at Roth Capital
Roth Capital analyst Darren Aftahi raised his price target for Stamps.com to $305 from $255 as he expects slightly above consensus results when the company reports Q2 results. His SHOP customer checks suggest 200bps improvement in Shipping penetration along with healthy merchant underlying business growth. This serves as one positive data point that gives the analyst comfort in his above consensus estimate. Aftahi reiterates a Buy rating on the shares.
10/18/18
CHLM
10/18/18
NO CHANGE
Target $300
CHLM
Buy
Reaction to Trump decision to leave Universal Postage Union 'naive,' says Craig-Hallum
Craig-Hallum analyst George Sutton notes that Stamps.com was under significant pressure from the announced move by Trump to leave the Universal Postage Union, which will increase prices on certain package shipments from China to the U.S. If there is any impact from the move, an effective tariff on the landed price of Chinese made products, it will result in a modest benefit to the U.S. based e-commerce retailers, which do ship volume through the Stamps.com network, he contends. Moreover, Sutton argues that the stock traded down on an item that if enacted would likely have a modest positive impact on the revenue opportunity. He believes that this is "naive" and has set the stock up very well for outsized gains ahead. The analyst reiterates a Buy rating and $300 price target on the stock.

TODAY'S FREE FLY STORIES

GKOS

Glaukos

$71.40

0.31 (0.44%)

05:46
04/26/19
04/26
05:46
04/26/19
05:46
Hot Stocks
Glaukos enters collaboration, distribution agreement with Santen »

Santen Pharmaceutical and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 05

    Jun

  • 13

    Nov

NITE

Nightstar Therapeutics

$25.61

0.08 (0.31%)

, BIIB

Biogen

$229.78

5.46 (2.43%)

05:43
04/26/19
04/26
05:43
04/26/19
05:43
Hot Stocks
Nightstar: ISS, Glass Lewis recommend holders vote 'FOR' deal with Biogen »

Nightstar Therapeutics…

NITE

Nightstar Therapeutics

$25.61

0.08 (0.31%)

BIIB

Biogen

$229.78

5.46 (2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 04

    May

  • 29

    May

SNY

Sanofi

$41.27

-0.2 (-0.48%)

05:41
04/26/19
04/26
05:41
04/26/19
05:41
Earnings
Sanofi backs FY19 business EPS growth of 3%-5% at CER »

Sanofi continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 31

    May

  • 26

    Jun

SNY

Sanofi

$41.27

-0.2 (-0.48%)

05:39
04/26/19
04/26
05:39
04/26/19
05:39
Earnings
Sanofi reports Q1 business EPS EUR 1.42 vs. EUR 1.28 »

Reports Q1 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 31

    May

  • 26

    Jun

AZN

AstraZeneca

$39.07

0.35 (0.90%)

05:36
04/26/19
04/26
05:36
04/26/19
05:36
Earnings
AstraZeneca backs FY19 core EPS view of $3.50-$3.70 »

Backs FY19 product sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 31

    May

  • 20

    Jun

AZN

AstraZeneca

$39.07

0.35 (0.90%)

05:32
04/26/19
04/26
05:32
04/26/19
05:32
Earnings
AstraZeneca reports Q1 reported EPS 47c, consensus 42c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 31

    May

  • 20

    Jun

PRO

Pros Holdings

$45.06

-0.25 (-0.55%)

05:29
04/26/19
04/26
05:29
04/26/19
05:29
Recommendations
Pros Holdings analyst commentary  »

Pros Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

ILMN

Illumina

$318.91

4.47 (1.42%)

05:27
04/26/19
04/26
05:27
04/26/19
05:27
Recommendations
Illumina analyst commentary at Piper Jaffray »

Illumina earnings selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 31

    May

  • 06

    Aug

  • 03

    Sep

ALGT

Allegiant Travel

$139.70

6.33 (4.75%)

05:22
04/26/19
04/26
05:22
04/26/19
05:22
Recommendations
Allegiant Travel analyst commentary at Imperial Capital »

Allegiant Travel price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

NFLX

Netflix

$368.20

-5.99 (-1.60%)

05:19
04/26/19
04/26
05:19
04/26/19
05:19
Recommendations
Netflix analyst commentary at Imperial Capital »

Imperial trims Netflix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

05:16
04/26/19
04/26
05:16
04/26/19
05:16
Recommendations
Amazon.com analyst commentary at Piper Jaffray »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 22

    May

  • 03

    Jun

SBUX

Starbucks

$77.07

0.65 (0.85%)

05:11
04/26/19
04/26
05:11
04/26/19
05:11
Downgrade
Starbucks rating change at Wells Fargo »

Starbucks downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

, ONCE

Spark Therapeutics

$111.40

0.73 (0.66%)

05:10
04/26/19
04/26
05:10
04/26/19
05:10
Hot Stocks
Roche, Spark Therapeutics withdraw, refile premerger notification »

Roche (RHHBY) and Spark…

RHHBY

Roche

$0.00

(0.00%)

ONCE

Spark Therapeutics

$111.40

0.73 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 03

    May

  • 04

    May

  • 28

    May

  • 31

    May

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

VCRA

Vocera

$31.31

0.36 (1.16%)

05:10
04/26/19
04/26
05:10
04/26/19
05:10
Recommendations
Vocera analyst commentary at Piper Jaffray »

Vocera positioned for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 28

    May

  • 05

    Jun

ESPR

Esperion

$43.02

1.14 (2.72%)

05:06
04/26/19
04/26
05:06
04/26/19
05:06
Upgrade
Esperion rating change  »

Esperion upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 07

    May

MDCO

The Medicines Co.

$29.84

0.37 (1.26%)

05:05
04/26/19
04/26
05:05
04/26/19
05:05
Upgrade
The Medicines Co. rating change  »

The Medicines Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 08

    May

RS

Reliance Steel

$91.29

2.46 (2.77%)

05:03
04/26/19
04/26
05:03
04/26/19
05:03
Downgrade
Reliance Steel rating change  »

Reliance Steel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TAL

TAL Education

05:02
04/26/19
04/26
05:02
04/26/19
05:02
Downgrade
TAL Education rating change  »

TAL Education downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASAZY

Assa Abloy

$0.00

(0.00%)

05:01
04/26/19
04/26
05:01
04/26/19
05:01
Downgrade
Assa Abloy rating change at Jefferies »

Assa Abloy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

BKU

BankUnited

$36.10

-0.39 (-1.07%)

05:00
04/26/19
04/26
05:00
04/26/19
05:00
Downgrade
BankUnited rating change  »

BankUnited downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TIGO

Millicom

$57.40

-1.25 (-2.13%)

04:59
04/26/19
04/26
04:59
04/26/19
04:59
Upgrade
Millicom rating change  »

Millicom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$151.26

-5.52 (-3.52%)

04:56
04/26/19
04/26
04:56
04/26/19
04:56
Upgrade
Illinois Tool Works rating change  »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

AXTA

Axalta Coating

$26.71

0.21 (0.79%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Downgrade
Axalta Coating rating change  »

Axalta Coating downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

KRP

Kimbell Royalty Partners

$18.00

0.02 (0.11%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Conference/Events
Kimbell Royalty Partners management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

CYAD

Celyad

$20.60

(0.00%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Conference/Events
Celyad management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.